The growth of GLP-1 treatment within diabetes Glucagon-like peptide 1 (GLP-1) receptor agonists have taken the healthcare world by storm, becoming one of the most successful drug classes of all time, reaching an astonishing $110 billion in sales in 2024 alone 1
In fact, when you look at some of the clinical research, users are just eating fewer candy bars but theyre still eating candy bars. Badaracco listed what she called GLP-1 meal allies that product developers can use when formulating products for GLP-1 users
Since both retatrutide and tirzepatide are made by Eli Lilly, the transition should be straightforward
Imagine feeling like you always have to eat for 20 years'
Declared that medications should be used alongside intensive behavioral therapy , not instead of it, says John
Like many medications, the effectiveness of retatrutide depends heavily on the correct dosage